波音游戏源码-波音博彩公司评级_百家乐园天将_新全讯网3344111.c(中国)·官方网站

Beneficiaries

22 Dec 2019

Safeguarding well-being through biomedical science - Named Professorship Scheme promotes excellence in research

Technological innovation holds great promise for the medical field, and one of the top scientists at CityUHK is dedicated to bridging these two domains.

Professor Michael Yang Mengsu

Yeung Kin Man Chair Professor of Biomedical Sciences
Senior Vice-President (Innovation and Enterprise)
Director (Tung Biomedical Sciences Centre)
Director (Biotechnology & Health Centre)

Full Story

Professor Michael Yang Mengsu, Yeung Kin Man Chair Professor of Biomedical Sciences, is seeking to improve people’s lives by converting his research into clinical applications.

“The ultimate goal of biomedical research is to contribute to human well-being. We hope to encourage more students to find and develop their passions for research and innovation and cultivate an entrepreneurial mindset for the challenge of converting CityUHK’s many high-quality research projects into clinical applications that benefit society,” Professor Yang said.

Professor Yang’s research activities focus on the study of the biological processes involved in cancer and the development of biochip technology and nanotechnology for molecular diagnostics and therapeutic applications. He has published more than 200 peer-reviewed papers, received 30 US / China patents and co-founded three spin-off biotech companies since joining CityUHK in 1994. He was awarded the Chunhui Scholar Award by the Ministry of Education in China in 2003, the K. C. Wong Foundation Award in 2004, the Shenzhen Science and Technology Innovation Award in 2006, the Hong Kong Technological Achievement Grand Award in 2007, the Natural Science Award by the Ministry of Education in 2015, and the Wuxi AppTech Life Science and Chemistry Award in 2016.

His latest work won a Gold Medal for a microfluidicsbased technology platform for disease diagnosis and drug screening at the 47th International Exhibition of Invention of Geneva in Switzerland in April 2019. The microfluidic chips can be used for the sensitive detection of multiple gene mutations on barcoded microbead arrays.

This process enables the early identification of infectious pathogens and tumour cells. The platform can also be used to generate arrays of single cells and tumour spheroids for screening the most efficient anti-cancer drugs with their optimal dosages. The patented technology has been licensed to a CityUHK spin-off company that was co-founded recently by three PhD students who graduated from Professor Yang’s laboratory.

Microfluidics Array Technology with Nano-Amplification for Drug Screening and Molecular Diagnosis
“Microfluidics Array Technology with Nano-Amplification for Drug Screening and Molecular Diagnosis”, developed by a research team led by Professor Michael Yang Mengsu.

 

Professor Yang has already turned several research projects into clinical applications. His group previously developed DNA chip technology for the early detection of cervical cancer. That application has been commercialised by a Shenzhen-based company co-founded in 2004 by one of his PhD graduates. Millions of women have benefited from the breakthrough. In addition, a company he helped establish with a PhD graduate and a post-doctoral fellow in Hong Kong in 2010 provides pharmacogenomics and assessment services for side effects from drugs and then suggests relevant preventive measures.

He thanked Dr Yeung Kin-man for supporting the Named Professorship Scheme. With the support of donors, this new scheme aims to promote excellence in research and professional education in the University’s distinguished research areas.

Dr and Mrs Yeung Kin-man
Dr and Mrs Yeung Kin-man at the donation ceremony in 2015. Dr Yeung’s donation supports University’s strategic developments and is used to establish Yeung Kin-man Chair Professorships in the University’s distinguished areas. In addition to biomedical sciences, the areas include
finance, IT innovation and management, media art and neuroscience.

 

These areas include architecture, behavioural and policy sciences, biomedical sciences, data science, data engineering, energy and environment, engineering, environmental veterinary medicine, finance, international economics, information engineering, IT innovation and management, media art, nanomaterials, neuroscience, nuclear engineering, translational neuroscience, and One Health.

“Donations have enabled my students and me to carry out pioneering biomedical research and innovations. We will continue to work hard to develop new technologies that benefit more and more people,” he said.

Research in CityUHK Biomedical Sciences brings new hope and opportunities


In addition to Professor Yang’s efforts to improve people’s lives by converting his research into clinical applications, faculty in CityUHK’s Department of Biomedical Sciences are dedicated to contributing to human betterment through their pioneering research. Associate Professor Dr Yao Xi developed a world-first, self-healable, anti-smudge coating, which enhances medical and aerospace equipment (details); Assistant Professor Dr Chow Kwan-ting studied rare cells that provide insights into developing cancer immunotherapy (details); and Assistant Professor Dr Ban Ki-won developed the first dual stem cell therapy for cardiac repair (details). These research achievements in biomedical science bring new hope and promise new opportunities for safeguarding human well-being.

发中发百家乐官网的玩法技巧和规则| 网上百家乐官网内幕| 百家乐法则| 百家乐官网网址哪里有| 找查百家乐玩法技巧| 百家乐官网投注方法多不多| 百家乐智能系统| 百家乐官网心得打法| 冠军娱乐城| 百家乐鸿泰棋牌| 凤翔县| 玩百家乐游戏经验| 时时博在线娱乐城| 中华百家乐娱乐城| 百家乐官网龙虎斗等| 百家乐官网家居 | 做生意办公桌摆放风水| 化德县| 威尼斯人娱乐城返佣| 大发888 894| 百家乐官网平游戏| 百家乐官网庄闲收益率| 网络老虎机| 威尼斯人娱乐城易博lm0| 澳门赌百家乐官网的玩法技巧和规则 | 澳门百家乐网40125| 澳门百家乐官网图形| 必博国际| 百家乐技巧| 百家乐投注限额| 百家乐官网网上赌有作假吗| 真人百家乐官网现金游戏| 机械手百家乐的玩法技巧和规则| 百家乐官网游戏大厅下| 乐宝百家乐官网游戏| 大发888充钱| 百家乐怎么玩最保险| 百家乐必胜软件下载| 自贡百家乐官网赌| 百家乐官网园鼎丰娱乐城| 百家乐官网视频无法显示|